CardioCampus

Canadian Perspectives on the ESC 2025

This webinar will focus on the latest research findings from international experts presented at the ESC 2025. These perspectives can impact profound changes and improvements in their clinical approach.

Program Learning Objectives:
- To review new data relevant to clinical practice
- To discuss the latest clinical trial data from ESC 2025 and apply it to daily practice

Program Chair and Moderator: Dr. Anil Gupta

Discussants: Dr. Gregory Hundemer, Dr. Neha Pagidipati, Dr. Subodh Verma and Dr. Derek Exner

Trials to be covered:

- Baxdrostat in patients with uncontrolled or resistant hypertension: BaxHTN Trial
- Zilebesiran in patients with uncontrolled hypertension and high CV risk: KARDIA-3 Trial
- Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery: NEWTON-CABG CardioLink-5 Trial
- Efficacy of ICD Therapy in Higher Risk Post-MI Patients With Better-Preserved LV Function: REFINE-ICD

When

10/1/2025 8:00 PM - 9:15 PM
Eastern Daylight Time

Where

Virtual CANADA

Registration

Registration is closed.

Contact: [email protected]

MOC Section 1 Credit(s)

1

Credit Type

Sec 1

Topic(s)

Late-Breaking Science

Programs

Canadian Perspectives (ACC,ESC,AHA)

CanMEDS

Medical Expert, Scholar

Target Audience

Cardiologist

Share this page

Annual Conference

CardioCampus

Canadian Perspectives on the ESC 2025

Social Media

Contact